Close
Achema middle east
swop processing & packaging

Pharma pioneer Sanofi guards its Dengvaxia

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

You do not get severe dengue from the vaccine. Just because you were administered with the vaccine means you’ll get infected. That’s s a little misinformation,” said Dr. Ruby Dizon, Sanofi Pasteur medical director.

“You get it because you had subsequent exposure to the virus, not because you were given the vaccine,” she added.

But still, Sanofi would not recommend vaccination for those who have not experienced dengue, according to Dr. Ng Su Peing, global medical head of the firm.

In a statement, Sanofi said that following their “supplementary exploratory analysis” of the long-term follow-up on the dengue vaccine, they found a clear and sustained benefit of being vaccinated with the dengue vaccine up to six years following the first injection for those individuals who were previously infected by dengue virus.

“In individuals who have not been previously infected by dengue virus, there is an increased risk of hospitalization for dengue and severe dengue, predominantly Grade I or II Dengue Hemorrhagic Fever (DHF),” Sanofi said in a statement.

Citing data from the World Health Organization, Sanofi said that “severe dengue” can be categorized from “milder to more severe forms as DHF I, II, III, and IV.”
It said that the DHF IV was not seen in individuals who were vaccinated.

“We have shared this new data in full transparency with the Philippine Food and Drug Administration (FDA) and the DOH.

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »